Omeros’ (OMER) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Omeros (NASDAQ:OMER) in a research note issued to investors on Thursday,Benzinga reports.

Several other equities analysts have also weighed in on the stock. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Rodman & Renshaw initiated coverage on Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price on the stock. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Finally, RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Omeros has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Omeros Stock Up 0.7 %

Shares of OMER stock opened at $10.31 on Thursday. The firm has a 50 day moving average of $7.09 and a 200-day moving average of $5.19. The company has a market cap of $597.46 million, a price-to-earnings ratio of -4.46 and a beta of 1.97. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60.

Institutional Investors Weigh In On Omeros

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP bought a new stake in shares of Omeros in the 3rd quarter worth $305,000. Bank of New York Mellon Corp grew its position in Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 31,081 shares in the last quarter. AQR Capital Management LLC purchased a new stake in Omeros in the 2nd quarter valued at about $105,000. SPC Financial Inc. bought a new position in shares of Omeros during the 3rd quarter worth approximately $77,000. Finally, Rhumbline Advisers boosted its stake in shares of Omeros by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after buying an additional 6,435 shares during the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.